SCHEMBL534925

SCHEMBL534925

c1cc2ccc3noccc3c2n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.48
CCR1 P32246 3/20 0.35
CCR5 P51681 3/20 0.35
CCR8 P51685 3/20 0.35
KDM4E B2RXH2 2/20 0.35
TP53 P04637 2/20 0.35
HSP90AA1 P07900 2/20 0.35
HTT P42858 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
TDP1 Q9NUW8 2/20 0.35
GMNN O75496 1/20 0.35
MMP2 P08253 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
MAPT P10636 1/20 0.35
MMP9 P14780 1/20 0.35
ALOX15 P16050 1/20 0.35
TSHR P16473 1/20 0.35
NFKB1 P19838 1/20 0.35
MMP8 P22894 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26688602 0.86 LMNA (0.51) LMNACCR1CCR5CCR8KDM4E
SCHEMBL2046270 0.74 LMNA (0.59) LMNACCR1CCR5CCR8KDM4E
SCHEMBL10923588 0.71 LMNA (0.78) LMNACCR1CCR5CCR8KDM4E
SCHEMBL9339299 0.71
SCHEMBL29199199 0.69
SCHEMBL6413480 0.69 MAPK10 (0.41) LMNAKDM4ETP53HTTSMN1; SMN2
SCHEMBL27375364 0.68 LMNA (0.96) LMNACCR1CCR5CCR8KDM4E
SCHEMBL5592200 0.68 LMNA (0.47) LMNACCR1CCR5CCR8KDM4E
SCHEMBL27975347 0.68 LMNA (0.56) LMNACCR1CCR5CCR8KDM4E
SCHEMBL7368978 0.68 LMNA (0.61) LMNACCR1CCR5CCR8KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4740152-B2 2011-08-03 JP claimed
EP-1097135-B1 PROCESS FOR THE PREPARATION OF AN INDOLE DERIVATIVE SMITHKLINE BEECHAM PLC (GB) 2008-05-07 EP claimed
US-20070254874-A1 Modulators of Preripheral 5-Ht Receptors BIO-MEDISINSK INNOVASJON (NO) 2007-11-01 US claimed
EP-1701951-A2 MODULATORS OF PERIPHERAL 5-HT RECEPTORS Bio-Medisinsk Innovasjon AS (NO) 2006-09-20 EP claimed
WO-2005061483-A2 MODULATORS OF PERIPHERAL 5-HT RECEPTORS BIO-MEDISINSK INNOVASJON AS (NO) 2005-07-07 WO claimed
US-5278158-A Heteropolycyclic pyridyl or pyridyl oxide YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 1994-01-11 US claimed
EP-0500319-A1 Oxazinobenzazole compounds YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 1992-08-26 EP claimed
CN-114790212-A Oxazinoindole and oxazinoisoquinoline compounds and process for preparing same 复旦大学 2022-07-26 CN disclosed
CN-114790212-A Oxazinoindole and oxazinoisoquinoline compounds and process for preparing same 复旦大学 2022-07-26 CN disclosed
US-20120094989-A1 5-HT RECEPTOR MODULATING COMPOUNDS SERODUS AS (NO) 2012-04-19 US disclosed
EP-2414331-A1 5-HT RECEPTOR MODULATING COMPOUNDS Serodus AS (NO) 2012-02-08 EP disclosed
CN-101463048-B Ruthenium complex inducing DNA conformation transition and preparation thereof UNIV SUN YAT SEN 2011-06-22 CN disclosed
US-7834010-B2 Modulators of peripheral 5-HT receptors SERODUS AS (NO) 2010-11-16 US disclosed
US-4012511-A ANTIULCER AGENTS AYERST MCKENNA & HARRISON LTD. (CA) 1977-03-15 US disclosed
US-4012511-A ANTIULCER AGENTS AYERST MCKENNA & HARRISON LTD. (CA) 1977-03-15 US disclosed
US-3962236-A ANTIDEPRESSANTS, ANTI-ULCER AYERST MCKENNA AND HARRISON LTD. (CA) 1976-06-08 US disclosed
US-3962236-A ANTIDEPRESSANTS, ANTI-ULCER AYERST MCKENNA AND HARRISON LTD. (CA) 1976-06-08 US disclosed
US-3912729-A Oxazinoindole- and thiazinoindole derivatives AYERST MCKENNA & HARRISON 1975-10-14 US disclosed
US-3910903-A Oxazinoindole- and thiazinoindole derivatives AYERST MCKENNA & HARRISON 1975-10-07 US disclosed
US-3910901-A Oxazinoindole- and thiazinoindole derivatives AYERST MCKENNA & HARRISON 1975-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254874-A1 Modulators of Preripheral 5-Ht Receptors HTR4, HTR5A, HTR6 LMNA 2805/4885CCR1 1663/4885CCR5 411/4885
US-20120094989-A1 5-HT RECEPTOR MODULATING COMPOUNDS HTR5A, HTR1A, HTR2A LMNA 730/4885CCR1 3570/4885CCR5 871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.